Embecta has completed its acquisition of UK-based medical device manufacturer Owen Mumford Holdings in a deal valued at up to £150m ($172.6m).
Initially announced in March 2026, the deal involves an upfront payment of £100m and up to £50m in additional payments tied to post-acquisition net sales of Owen Mumford’s Aidaptus auto-injector platform over three years.
The transaction supports embecta’s ongoing shift towards providing a broader range of medical supplies, including drug delivery platforms for pharmaceutical partners and products serving patients managing chronic conditions.
Embecta is targeting the needs of individuals living with anaphylaxis, obesity, diabetes, and autoimmune diseases.
This deal provides embecta with a specialised drug-delivery platform for multiple therapeutic areas and enhances its intellectual property portfolio, notably with the Aidaptus auto-injector platform.
The acquisition adds new chronic care devices and brings together Owen Mumford’s expertise in device design, moulding, and assembly with embecta’s commercial operations and large-scale manufacturing. The combination is expected to expand global market reach and improve operational efficiency.
Embecta aims to supply a range of medical products with a workforce of around 2,500 employees.
Owen Mumford focuses on healthcare device development, drug delivery technologies, and devices for chronic care and diagnostic use.
The company’s two-step, subcutaneous, single-use Aidaptus auto-injector has been designed to enable future pharmaceutical collaborations and streamlines the final assembly process by using a plunger rod insertion method that automatically adapts to different fill volumes.
This approach keeps a fixed distance between the stopper and plunger, regardless of fill volume, and reduces the need for additional verification.
